Literature DB >> 18435455

Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumour-associated cancer/testis antigen.

Juergen L Foell1, Manuela Hesse, Ines Volkmer, Benjamin J Schmiedel, Ingo Neumann, Martin S Staege.   

Abstract

BACKGROUND: Cancer/testis antigens (CTA) represent a heterogeneous group of antigens expressed nearly exclusively in tumour cells and testis. Recently, we identified phospholipase A1 beta (a CTA also known as lipase member I, LIPI) as a gene with high expression in Ewing family tumours (EFT). In the present paper we analyzed expression of LIPI in a panel of normal tissues and tumour samples. PROCEDURE: The expression of CTA in EFT and normal tissues was analyzed by using DNA microarray datasets. Expression of LIPI in EFT, a panel of other tumour samples, and normal tissues was analyzed by using RT-PCR and quantitative RT-PCR.
RESULTS: LIPI was expressed in EFT samples but not in other investigated tumour samples. Expression of LIPI in normal tissues was restricted to testis and thyroid. However, expression in these tissues was low compared with EFT. Interestingly testis as well as thyroid expressed all analyzed EFT-associated transcripts, suggesting that these tissues harbour a small cell population with molecular features of EFT. The sensitivity of the LIPI RT-PCR was similar to the sensitivity of the conventional EWSR1-FLI1 RT-PCR, suggesting that LIPI might be useful as additional diagnostic target structure.
CONCLUSIONS: The human cancer/testis antigen LIPI is highly expressed in Ewing family tumours and can be easily detected by RT-PCR or quantitative RT-PCR. LIPI might be an interesting target for the development of future diagnostic tools or treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435455     DOI: 10.1002/pbc.21602

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  16 in total

1.  EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells.

Authors:  Nicolò Riggi; Mario-Luca Suvà; Claudio De Vito; Paolo Provero; Jean-Christophe Stehle; Karine Baumer; Luisa Cironi; Michalina Janiszewska; Tanja Petricevic; Domizio Suvà; Stéphane Tercier; Jean-Marc Joseph; Louis Guillou; Ivan Stamenkovic
Journal:  Genes Dev       Date:  2010-04-09       Impact factor: 11.361

2.  Characterization of Ewing sarcoma associated cancer/testis antigens.

Authors:  Dorothea E Mahlendorf; Martin Sebastian Staege
Journal:  Cancer Biol Ther       Date:  2013-01-04       Impact factor: 4.742

3.  Expression of multiple membrane-associated phospholipase A1 beta transcript variants and lysophosphatidic acid receptors in Ewing tumor cells.

Authors:  Benjamin Joachim Schmiedel; Christoph Hutter; Manuela Hesse; Martin Sebastian Staege
Journal:  Mol Biol Rep       Date:  2010-12-04       Impact factor: 2.316

4.  Sequence and expression of the chicken membrane-associated phospholipases A1 alpha (LIPH) and beta (LIPI).

Authors:  Manuela Hesse; Edith Willscher; Benjamin J Schmiedel; Stefan Posch; Ralph P Golbik; Martin S Staege
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

Review 5.  Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

Authors:  Michael J Nathenson; Anthony P Conley; Edward Sausville
Journal:  Oncologist       Date:  2017-09-21

6.  Down-regulation of achaete-scute complex homolog 1 (ASCL1) in neuroblastoma cells induces up-regulation of insulin-like growth factor 2 (IGF2).

Authors:  Jialing Li; Ingo Neumann; Ines Volkmer; Martin Sebastian Staege
Journal:  Mol Biol Rep       Date:  2010-09-15       Impact factor: 2.316

7.  Current therapeutic approaches in metastatic and recurrent ewing sarcoma.

Authors:  Michael Huang; Kenneth Lucas
Journal:  Sarcoma       Date:  2010-12-01

8.  Immunotherapy targets in pediatric cancer.

Authors:  Rimas J Orentas; Daniel W Lee; Crystal Mackall
Journal:  Front Oncol       Date:  2012-01-30       Impact factor: 6.244

9.  RNA expression profiling reveals PRAME, a potential immunotherapy target, is frequently expressed in solitary fibrous tumors.

Authors:  Wei-Lien Wang; Nalan Gokgoz; Bana Samman; Irene L Andrulis; Jay S Wunder; Elizabeth G Demicco
Journal:  Mod Pathol       Date:  2020-10-02       Impact factor: 7.842

10.  Sarcoma immunotherapy.

Authors:  Launce G Gouw; Kevin B Jones; Sunil Sharma; R Lor Randall
Journal:  Cancers (Basel)       Date:  2011-11-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.